Albendazole is effective in the treatment of cutaneous larva migrans characterized by multiple and/or diffuse lesions. This new therapeutic regimen can reduce the number of no responses and recurrences, sometimes observed following shorter (e.g. 3-5 days) treatments with albendazole. The longer duration of treatment is not accompanied by the appearance of new and/or more severe side-effects.